Evidence map›Paper›PMID 29387345›Full record

ArticleAntimicrobial resistance and infection control2018

Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.

Allison Muller, Xavier Bertrand, Anne-Marie Rogues, Muriel Péfau, Serge Alfandari, Rémy Gauzit, Catherine Dumartin, Houssein Gbaguidi-Haore, ATB-RAISIN network steering committee

Abstract read
In one paragraph

Article in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allison Muller1University Hospital of Besançon, Infection Control Department, F-25030 Besançon, France.
Xavier Bertrand1University Hospital of Besançon, Infection Control Department, F-25030 Besançon, France.
Anne-Marie Rogues3University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France.
Muriel Péfau4CHU Bordeaux, Southwestern Centre for Infection Prevention and Control, F-33000 Bordeaux, France.
Serge AlfandariGustave Dron Hospital, Infectious Diseases Department, F-59208 Tourcoing, France.
Rémy Gauzit6AP-HP, Cochin University Hospital, Infectious Diseases Department, F-75014 Paris, France.
Catherine Dumartin3University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France.
Houssein Gbaguidi-Haore1University Hospital of Besançon, Infection Control Department, F-25030 Besançon, France.ORCID 0000-0002-1825-9358
ATB-RAISIN network steering committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The ongoing extended spectrum β-lactamase-producing Methods: This ward-level multicentre retrospective study was based on data from French antibiotic and multidrug-resistant bacteria surveillance networks in healthcare facilities. Antibiotic use was expressed in defined daily doses per 1000 patient-days. Factors associated with the reduction in carbapenem use (yes/no) over the study period were determined from random-effects logistic regression model (493 wards nested within 259 healthcare facilities): ward characteristics (type, size…), ward antibiotic use (initial antibiotic use [i.e., consumption of a given antibiotic in 2009], initial antibiotic prescribing profile [i.e., proportion of a given antibiotic in the overall antibiotic consumption in 2009] and reduction in the use of a given antibiotic between 2009 and 2013) and regional ESBL-PE incidence rate in acute care settings in 2011. Results: Over the study period, carbapenem consumption in ICUs ( Conclusions: Our study suggests that a decrease in 3GCs in the overall antibiotic use and the continuation of reduction in fluoroquinolone use, could allow reducing carbapenem use, given the well-demonstrated role of 3GCs and fluoroquinolones in the occurrence of ESBL-PE. Thus, antibiotic stewardship programs should target wards with higher 3GC prescription proportions to reduce them.

Indexed as

PrescriptionsAnti-Bacterial AgentsAntimicrobial Stewardshipbeta-Lactamasesbeta-Lactam ResistanceCarbapenemsCephalosporinsCross InfectionDrug Resistance, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsFluoroquinolonesFranceGlycopeptidesGuidelines as TopicHospitalsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCephalosporinsFluoroquinolonesGlycopeptidesPiperacillin, Tazobactam Drug CombinationAntibiotic stewardshipAntibiotic useCarbapenemESBLMultidrug-resistant bacteria

Identifiers

PMID29387345
PMCPMC5778631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.